- Home
- IFRX vs IMMX Comparison
IFRX vs IMMX Comparison
Compare IFRX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- IMMX
- Stock Information
- Founded
- IFRX 2007
- IMMX 2014
- Country
- IFRX Germany
- IMMX United States
- Employees
- IFRX N/A
- IMMX N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- IFRX Health Care
- IMMX Health Care
- Exchange
- IFRX Nasdaq
- IMMX Nasdaq
- Market Cap
- IFRX 86.0M
- IMMX 82.6M
- IPO Year
- IFRX 2017
- IMMX 2021
- Fundamental
- Price
- IFRX $1.77
- IMMX $3.28
- Analyst Decision
- IFRX Strong Buy
- IMMX Strong Buy
- Analyst Count
- IFRX 5
- IMMX 1
- Target Price
- IFRX $9.80
- IMMX $8.00
- AVG Volume (30 Days)
- IFRX 6.9M
- IMMX 769.8K
- Earning Date
- IFRX 11-07-2025
- IMMX 11-07-2025
- Dividend Yield
- IFRX N/A
- IMMX N/A
- EPS Growth
- IFRX N/A
- IMMX N/A
- EPS
- IFRX N/A
- IMMX N/A
- Revenue
- IFRX $73,729.00
- IMMX N/A
- Revenue This Year
- IFRX N/A
- IMMX N/A
- Revenue Next Year
- IFRX $1,216.24
- IMMX N/A
- P/E Ratio
- IFRX N/A
- IMMX N/A
- Revenue Growth
- IFRX N/A
- IMMX N/A
- 52 Week Low
- IFRX $0.71
- IMMX $1.34
- 52 Week High
- IFRX $2.82
- IMMX $4.05
- Technical
- Relative Strength Index (RSI)
- IFRX 63.15
- IMMX 55.27
- Support Level
- IFRX $1.16
- IMMX $2.85
- Resistance Level
- IFRX $1.48
- IMMX $3.53
- Average True Range (ATR)
- IFRX 0.20
- IMMX 0.38
- MACD
- IFRX 0.02
- IMMX -0.07
- Stochastic Oscillator
- IFRX 75.64
- IMMX 34.80
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.